A Phase 2 interventional study of NBI-98854 and NBI-98854 in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 11 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-10.
Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 11th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 2nd registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 2 started in 2011.
This study's enrollment of 37 is below the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 101 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
13 studies in Tardive Dyskinesia by Neurocrine Biosciences: 2 open now, 2 under way, none of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 13 studies in Tardive Dyskinesia by Neurocrine Biosciences, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 2, and was the 2nd registered.
Neurocrine Biosciences’s Tardive Dyskinesia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Neurocrine Biosciences’s 13 in Tardive Dyskinesia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses (12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive dyskinesia in subjects with schizophrenia or schizoaffective disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences: Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28. Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28.
Drug: NBI-98854 · Drug: Placebo
During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences: Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28. Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28.
Drug: NBI-98854 · Drug: Placebo
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
Time frame: Day 15 and 29, averaged
Clinical Global Impression - Global Improvement of TD (CGI-TD)
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
Time frame: Day 15 and 29, averaged
This study enrolled patients with a clinical diagnosis of schizophrenia or schizoaffective disorder with moderate or severe symptoms of tardive dyskinesia (TD) from 10 centers in the United States. The last patient completed in February 2012.
| Milestone | Placebo, Then Valbenazine 12.5 mg | Valbenazine 12.5 mg, Then Placebo | Placebo, Then Valbenazine 50 mg | Valbenazine 50 mg, Then Placebo |
|---|---|---|---|---|
| Started | 9 | 8 | 10 | 10 |
| Completed | 9 | 7 | 9 | 9 |
| Not completed | 0 | 1 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Milestone | Placebo, Then Valbenazine 12.5 mg | Valbenazine 12.5 mg, Then Placebo | Placebo, Then Valbenazine 50 mg | Valbenazine 50 mg, Then Placebo |
|---|---|---|---|---|
| Started | 9 | 7 | 9 | 9 |
| Completed | 9 | 7 | 7 | 8 |
| Not completed | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Milestone | Placebo, Then Valbenazine 12.5 mg | Valbenazine 12.5 mg, Then Placebo | Placebo, Then Valbenazine 50 mg | Valbenazine 50 mg, Then Placebo |
|---|---|---|---|---|
| Started | 9 | 7 | 7 | 8 |
| Completed | 9 | 7 | 6 | 8 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
| units on a scale | Placebo | Valbenazine 12.5 mg | Valbenazine 50 mg |
|---|---|---|---|
| Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score | 9.9 ± 0.7 | 9.1 ± 1.2 | 8.8 ± 1.2 |
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
| units on a scale | Valbenazine 12.5mg Placebo | Valbenazine 12.5mg | Valbenazine 50mg Placebo | Valbenazine 50mg |
|---|---|---|---|---|
| Clinical Global Impression - Global Improvement of TD (CGI-TD) | 2.2 ± 0.2 | 2.2 ± 0.2 | 3.2 ± 0.3 | 2.6 ± 0.3 |
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
| units on a scale | Placebo | Valbenazine 12.5 mg | Valbenazine 50 mg |
|---|---|---|---|
| Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score for Combined NBI-98854 Dose Groups (Excluding 1 Site) | 10.3 ± 0.9 | 9.9 ± 1.1 | 6.1 ± 1.2 |
Collected over up to 35 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/35 (0%) | 0/35 (0%) | 4/35 (11.4%) |
| NBI-98854 12.5 mg | 0/17 (0%) | 1/17 (5.9%) | 4/17 (23.5%) |
| NBI-98854 50 mg | 0/19 (0%) | 0/19 (0%) | 6/19 (31.6%) |
| Event | Placebo | NBI-98854 12.5 mg | NBI-98854 50 mg |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/35 | 1/17 | 0/19 |
| Event | Placebo | NBI-98854 12.5 mg | NBI-98854 50 mg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/35 | 1/17 | 0/19 |
| VomitingGastrointestinal disorders | 0/35 | 1/17 | 0/19 |
| FuruncleInfections and infestations | 0/35 | 1/17 | 1/19 |
| Urine analysis abnormalInvestigations | 0/35 | 1/17 | 0/19 |
| Back painMusculoskeletal and connective tissue disorders | 2/35 | 1/17 | 0/19 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 0/35 | 1/17 | 0/19 |
| HeadacheNervous system disorders | 2/35 | 1/17 | 0/19 |
| ParaesthesiaNervous system disorders | 0/35 | 1/17 | 0/19 |
| FatigueGeneral disorders | 2/35 | 0/17 | 0/19 |
| Vision blurredEye disorders | 0/35 | 0/17 | 1/19 |
| Age, Continuous(years) | All Subjects |
|---|---|
| Mean | 51.1 (29 to 65) |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 15 |
| Male | 22 |
| Race/Ethnicity, Customized(Participants) | All Subjects |
|---|---|
| Black | 12 |
| Caucasian | 15 |
| Hispanic | 10 |
| Body Mass Index(kg/m^2) | All Subjects |
|---|---|
| Mean | 29.9 (18.1 to 42.0) |
| Age of Schizophrenia/Schizoaffective Disorder Diagnosis(years) | All Subjects |
|---|---|
| Mean | 25.8 (8 to 54) |
| Age at TD Diagnosis(years) | All Subjects |
|---|---|
| Mean | 41.7 (18 to 63) |
The record gives a start of Aug 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 5 years 6 months after primary completion. A results delay was requested in Apr 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine